Journals / Türk Biyokimya Dergisi / 2016 / Cilt: 41 - Sayı: 4

Kronik hepatit B hastalarında serum insülin benzeri büyüme faktörü 1 (IGF-1) ve insülin benzeri büyüme faktörü bağlayıcı protein 3 (IGFBP-3) düzeyleri

Serum insulin-like growth factor-1 and insulin-like growth factor binding protein-3 levels in patients with chronic hepatitis B

Pages
263–268
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

IGF-1 and IGFBP-3 levels in chronic HBV patientswere negatively correlated with serum transaminases.Conclusion: We conclude that serum levels of IGF-1 andIGFBP-3 may be useful markers for liver dysfunction inpatients with HBV-induced chronic liver disease.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Decreased serum insulin-like growthfactor-1 (IGF-1) and insulin like growth factor bindingprotein-3 (IGFBP-3) levels have been found in patientswith chronic liver disease of different etiologies, but thesefactors have not been studied extensively in patients withhepatitis B virus (HBV)-induced chronic liver disease.Methods: We have investigated serum IGF-1 and IGFBP-3levels in 40 patients with chronic HBV and 40 patientswith HBV-induced cirrhosis.
📊
Key Findings & Data:IGF-1 and IGFBP-3 levels were measuredby immunochemiluminescence.
💡
Conclusion & Impact:IGF-1 and IGFBP-3 levels in chronic HBV patientswere negatively correlated with serum transaminases.Conclusion: We conclude that serum levels of IGF-1 andIGFBP-3 may be useful markers for liver dysfunction inpatients with HBV-induced chronic liver disease.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Decreased serum insulin-like growthfactor-1 (IGF-1) and insulin like growth factor bindingprotein-3 (IGFBP-3) levels have been found in patientswith chronic liver disease of different etiologies, but thesefactors have not been studied extensively in patients withhepatitis B virus (HBV)-induced chronic liver disease.Methods: We have investigated serum IGF-1 and IGFBP-3levels in 40 patients with chronic HBV and 40 patientswith HBV-induced cirrhosis. According to Child-Pughclassification cirrhotic patients were divided into threegroups. Forty age-and sex-matched healthy subjectsserved as controls. IGF-1 and IGFBP-3 levels were measuredby immunochemiluminescence. The results werecompared with those for serum albumin, total bilirubin,transaminase activity, and with prothrombin time.Results: IGF-1 and IGFBP-3 levels were significantly lowerin patients with cirrhosis than in those with chronicHBV and in controls (p< 0.001). In chronic HBV patients,IGFBP-3 levels were significantly lower than in controls(p=0.013). IGF-1 and IGFBP-3 levels were significantlylower in cirrhotic patients with Child-Pugh stage B andChild-Pugh stage C compared with Child-Pugh stage A(for IGF-1 p=0.037 and p< 0.001, for IGFBP-3 p=0.036 andp< 0.001, respectively). In patients with Child-Pugh stage Csignificantly IGF-1 levels were lower than in patients withChild-Pugh stage B (p=0.003). IGF-1 and IGFBP-3 levelswere positively correlated with serum albumin concentrationsand negatively correlated with serum total bilirubinand prothrombin time concentrations in cirrhoticpatients. IGF-1 and IGFBP-3 levels in chronic HBV patientswere negatively correlated with serum transaminases.Conclusion: We conclude that serum levels of IGF-1 andIGFBP-3 may be useful markers for liver dysfunction inpatients with HBV-induced chronic liver disease.

Özet

Amaç: Farklı etyolojilere bağlı kronik karaciğer hastalığı olan hastalarda serum insülin benzeri büyüme faktörü 1 (IGF-1) ve insülin benzeri büyüme faktörü bağlayıcı protein 3 (IGFBP-3) düzeyleri düşük bulunmuştur, fakat bu parametreler hepatit B virüsüne (HBV) bağlı kronik karaciğer hastalığı olan hastalarda geniş çapta çalışılmamıştır.Metod: Bu çalışmada kronik HBV'li 40 hasta ve HBV'ye bağlı sirozu olan 40 hasta çalışmaya dahil edildi. ChildPugh sınıflandırmasına göre sirozlu hastalar üç gruba ayrıldı. Yaş ve cinsiyet uyumlu 40 sağlıklı birey kontrol grubu olarak kullanıldı. IGF-1 ve IGFBP-3 düzeyleri immünokemilüminesans yöntemle ölçüldü. Sonuçlar serum albümini, total bilirübin, transaminaz aktiviteleri ve protrombin zamanı ile karşılaştırıldı.Bulgular: IGF-1 ve IGFBP-3 düzeyleri sirozlu hastalarda kronik HBV'li ve kontrollere göre belirgin olarak düşüktü (p< 0.001). Kronik HBV'li hastalarda IGFBP-3 düzeyleri kontrollere göre belirgin olarak düşüktü (p=0.013). Serum IGF-1 ve IGFBP-3 düzeyleri siroz hastalarında Child-Pugh B ve Child-Pugh C gruplarında Child-Pugh A grubuna göre belirgin olarak düşüktü (sırasıyla IGF-1 için p=0.037 ve p< 0.001; IGFBP-3 için p=0.036 ve p< 0.001). Serum IGF-1 düzeyleri Child-Pugh C grubunda Child-Pugh B grubuna göre belirgin olarak düşüktü (p=0.003). Siroz hastalarında IGF-1 ve IGFBP-3 düzeyleri serum albümin konsantrasyonu ile pozitif, protrombin zamanı ve serum total bilirübin konsantrasyonu ile negatif korelasyon göstermekteydi. Kronik HBV'li hastalarda IGF 1 ve IGFBP-3 düzeyleri serum transaminazlarıyla ise negatif korelasyon göstermekteydi.Sonuç: HBV'ye bağlı kronik karaciğer hastalığı olan hastalarda IGF-1 ve IGFBP-3 karaciğer bozukluğunu değerlendirmekte yararlı belirteçler olabilir

🔖

Cite This Article

HAKLAR, G., YAMAN, A., KIZILTAŞ, Ş., İMERYÜZ, N., ULUSOY, C. (2022). Kronik hepatit B hastalarında serum insülin benzeri büyüme faktörü 1 (IGF-1) ve insülin benzeri büyüme faktörü bağlayıcı protein 3 (IGFBP-3) düzeyleri. Türk Biyokimya Dergisi, Cilt: 41 - Sayı: 4, 263–268. https://ajindex.com/articles/621023

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Sharma SK, Saini N, Chwla Y. Hepatitis B virus: inactive carriers. Virol J 2005; 2:82
  2. Durand F, Valla D. Assessment of prognosis of cirrhosis. Semin Liver Dis 2008; 28(1):110–22
  3. Juul A. Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Horm IGF Res 2003; 13(4):113–70
  4. Castro GR, Coelho JC, Parolin MB, Matias JE, de Freitas AC. Insulin-like growth factor I correlates with MELD and returns to normal level after liver transplantation. Ann Transplant 2013; 18:57–62
  5. Ottesen LH, Bendtsen F, Flyvbjerg A. The insulin-like growth factor binding protein 3 ternary complex is reduced in cirrhosis. Liver 2001; 21(5):350–6
  6. Vyzantiadis T, Theodoridou S, Giouleme O, Harsoulis P, Evgenidis N, Vyzantiadis A. Serum concentrations of insulin-like growth factor-I (IGF-I) in patients with liver cirrhosis. Hepatogastroenterology 2003; 50(51):814–6
  7. Lorenzo-Zúñiga V, Bartolí R, Masnou H, Montoliu S, Morillas RM, Planas R. Serum concentrations of insulin-like growth factor-I (igf-I) as a marker of liver fibrosis in patients with chronic hepatitis C. Dig Dis Sci 2007; 52(11):3245–50
  8. Wu YL, Ye J, Zhang S, Zhong J, Xi RP. Clinical significance of serum IGF-I, IGF-II and IGFBP-3 in liver cirrhosis. World J Gastroenterol 2004; 10(18):2740–3
  9. Chui SH, Chan K, Chui AK, Shek LS, Wong RN. The effects of a Chinese medicinal suppository (Vitalliver) on insulin-like growth factor 1 and homocysteine in patients with hepatitis B infection. Phytother Res 2005; 19(8):674–8
  10. Ding HG, Shan J, Zhang B, Ma HB, Zhou L, Jin R, et al. Combined human growth hormone and lactulose for prevention and treatment of multiple organ dysfunction in patients with severe chronic hepatitis B. World J Gastroenterol 2005; 11(19):2981–3
  11. Durand F, Valla D. Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J Hepatol 2005;42 Suppl(1):S100–7
  12. Bonefeld K, Møller S. Insulin-like growth factor-I and the liver. Liver Int 2011; 31(7):911–9
  13. Ronsoni MF, Lazzarotto C, Fayad L, Silva MC, Nogueira CL, et al. IGF-I and IGFBP-3 serum levels in patients hospitalized for complications of liver cirrhosis. Ann Hepatol 2013; 12(3):456–63
  14. Colakoğlu O, Taşkiran B, Colakoğlu G, Kizildağ S, Ari Ozcan F, et al. Serum insulin like growth factor-1 (IGF-1) and insulin like growth factor binding protein-3 (IGFBP-3) levels in liver cirrhosis. Turk J Gastroenterol 2007; 18(4):245–9
  15. Okan A, Cömlekçi A, Akpinar H,